Mexico Pharmaceuticals & Healthcare Report Q4 2014

Aug 15, 2014 - Business Monitor International - 145 pages - USD $1,295
Abstract Table of Contents Request Details Related
The lack of a unified reimbursement system, the absence of widespread private health insurance, relatively low healthcare spending and the promotion of generic drugs in Mexico will continue to undermine revenue-generating opportunities for innovative drugmakers. However, over the long term, healthier fiscal revenue due to energy reform will encourage the Mexican government to further increase public spending on medical services and improve national healthcare standards. .

Headline Expenditure Projections
  • Pharmaceuticals: MXN171.4bn (USD13.4bn) in 2013 to MXN182.4bn (USD14.2bn) in 2014; +6.4% in local currency terms and +5.7% in US dollar terms. Forecast decreased from Q 3 14 due to increasing generic competition.
  • Healthcare: MXN953.1bn (USD72.46bn) in 2013 to MXN1,031.6bn (USD86.96bn) in 2014; +8.3% in local currency terms and +7.6% in US dollar terms. Forecast de creased from Q 3 14 due to revised historical data .
Risk/Reward Rating

Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fifth-most attractive pharmaceutical market in the region.

Key Trends And Developments
  • In July 2014, Swiss drugmaker Roche Diagnostic launched its first diagnostic innovation in Mexico.
  • In June 2014 Mexico's health ministry began the first consolidated drug purchasing, which will supply the pharmaceutical sector until December. Around MXN500mn (USD38.29mn) will be invested to purchase all kinds of drugs from 80 approved laboratories.
  • In June 2014, Mexico's Eighth Judicial District Court has denied sanction to US-based drugmaker Merck that sought to extend the 20-year patent for a cancer drug, Zolinza (vorinostat).
  • In May 2014, Mexico's Federal Commission for Protection against Health Risks (Cofepris) announced that the health ministries of Mexico and South Korea have collaborated to promote the exchange of medicines, medical equipment and cosmetics between the two countries.
  • In May 2014, Endo...

The Mexico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mexico Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mexican pharmaceutical and healthcare industry.

Key Benefits
  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Mexico to test other views - a key input for successful budgeting and strategic business planning in the Mexican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mexican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mexico.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

Order This Report
FORMAT: PDF - Download Now with 3 Quarterly Updates $1,295 USD
LICENSE: Single-User
DELIVERY: Instant Download

Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away

About the Publisher
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.